Achieve Life Sciences will announce its first quarter 2026 financial results and provide a corporate update on May 12, 2026. The company is focused on developing cytisinicline, a plant-based drug aimed at treating nicotine dependence for smoking and vaping cessation. Cytisinicline's New Drug Application was accepted by the FDA in September 2025, with a review deadline set for June 20, 2026. This drug addresses a significant public health need, as millions of adults in the U.S. smoke or vape, and there are currently no FDA-approved treatments specifically for e-cigarette cessation.
Resonate introduced Signature Segmentation, a new service that transforms first-party customer data into distinct audience groups based on motivations rather than just demographics or past behavior. This approach helps brands understand why customers...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.26% ownership stake in Prologis Inc, totaling 11,789,090 shares as of July 27, 2026. This disclosure is made under Rule 8.3 of the Takeover Code, indicating a significant investment po...
SLC Digital has expanded its Board of Directors and Strategic Advisory Board as it enters a new phase of commercial growth following a strategic investment led by C7, a 7RIDGE subsidiary. The new leadership includes experienced executives from techno...
Investec Bank plc, acting as a joint broker for Gamma Communications Plc, disclosed a public dealing on July 27, 2026, involving the purchase and sale of 96,419 ordinary shares of Gamma Communications. The transactions were executed at prices ranging...
Investec Bank plc, acting as advisor and broker for Gooch & Housego plc, disclosed public dealings under the Takeover Code on July 27, 2026. The bank purchased 8,073 ordinary shares at prices between 1220 and 1230 pence and sold 6,000 shares at price...
